Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
BioMarin Pharmaceutical
American company
Related events
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.
- Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.
- Applied DNA Sciences and BioMarin Pharmaceutical are identified as competing companies within the healthcare market.
Coverage
Newest first; wire copies grouped- Insider MonkeyLeerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top most undervalued biotech stocks to buy now.
- Insider MonkeyLeerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to invest in now. On July